TRYHARD, a randomized phase II trial (RTOG Foundation 3501) of concurrent accelerated radiation plus cisplatin (cis) with or without lapatinib (Lap) for stage III- IV Non-HPV head and neck carcinoma (HNC).

Stuart J. Wong,Pedro A. Torres-Saavedra,Nabil F. Saba,George Shenouda,Jeffrey M. Bumpous,Robert E. Wallace,Christine H. Chung,Adel K. El-Naggar,Clement K. Gwede,Barbara Burtness,Paul Tennant,Neal Dunlap,Loren K. Mell,Sharon A. Spencer,William A. Stokes,Min Yao,D. L. Mitchell,Jonathan Harris,Walter J. Curran,Quynh-Thu Le

TRYHARD, a randomized phase II trial (RTOG Foundation 3501) of concurrent accelerated radiation plus cisplatin (cis) with or without lapatinib (Lap) for stage III- IV Non-HPV head and neck carcinoma (HNC).

2021

6014Background: Chemoradiation (CRT) with cis or anti-EGFR Ab has been shown to improve survival of patients with stage III-IV HNC. Since Lap, a dual EGFR and HER2 inhibitor, has shown effectivenes...

Keywords:

Internal medicine
Medicine
Oncology
Cisplatin
Stage (cooking)
Lapatinib
head and neck carcinoma

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations